Noveome Biotherapeutics, Inc.
Transforming the way challenging diseases and conditions are treated.
Transforming the way challenging diseases and conditions are treated.
Noveome Biotherapeutics, Inc. is a dynamic biopharmaceutical company based in the United States that is passionate about transforming the way challenging diseases and conditions are treated. Founded in 2000 and formerly known as Stemnion, Inc., the company is dedicated to breakthrough therapies for the regenerative repair of inflamed or damaged tissues.
Unlike traditional drugs, Noveome's product represents a paradigm shift in drug development, utilizing a complex mixture of biomolecules with the potential to treat a wide range of conditions and injuries. The company has been a pioneer in collaborating with major research centers to advance these therapeutic applications.
The most recent Series E investment of $20.70M was secured on 17 August 2023 from MAK Capital, further fueling Noveome's innovative platform technology. Noveome is headquartered near the Southside Works in Pittsburgh and is committed to helping the region become a world leader in biotherapeutic research and development within the industries of Biotechnology and Health Care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series E | $20.70M | 1 | MAK Capital | 17 Aug 2023 |
| Venture Round | $870.00K | - | 02 Oct 2020 | |
| Grant | $4.00M | 1 | Government of Pennsylvania | 07 May 2020 |
| Series D | $15.00M | - | 10 Apr 2019 | |
| Venture Round | $2.16M | - | 14 Apr 2016 |
No recent news or press coverage available for Noveome Biotherapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.
